Physician profile
Sean E Gilin
NPI 1811099567
$6,754.90
in general payments reported to CMS, 2019-2025
44 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $446 · 2021: $1,181 · 2022: $1,238 · 2023: $1,223 · 2024: $1,171 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,344 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.83 |
| Education | $160.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $835.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $668.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $641.61 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $466.89 | 2019-2025 | |
| Amgen INC. | $432.82 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $393.17 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $376.66 | 2019-2025 | |
| Exact Sciences Corporation | $336.82 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $286.00 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $249.50 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $249.35 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.66 | 2019-2024 | Jardiance, Ofev |
| Abbott Laboratories | $145.86 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biogen, INC. | $143.24 | 2019-2025 | Skyclarys, Skyclarys |
| Bayer Healthcare Pharmaceuticals INC. | $124.54 | 2021-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Gilin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.